Zaltrap: new treatment option for metastatic colorectal cancer

Zaltrap (aflibercept) is licensed for the treatment of metastatic colorectal cancer that is resistant to or has progressed following oxaliplatin therapy, in combination with irinotecan, 5-FU and folinic acid (FOLFIRI).

 Zaltrap is administered by intravenous infusion over 1 hour every two weeks and is continued until disease progression or unacceptable toxicity
Zaltrap is administered by intravenous infusion over 1 hour every two weeks and is continued until disease progression or unacceptable toxicity

PHARMACOLOGY 

Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) receptors 1 and 2. By binding to these receptors, it reduces the growth of blood vessels that supply tumours with oxygen and nutrients.1

CLINICAL STUDIES

Aflibercept was investigated in a randomised, double-blind trial in 1,226 patients with metastatic colorectal cancer who had previously received oxaliplatin therapy, with or without prior bevacizumab.2

The addition of aflibercept to FOLFIRI significantly improved median survival relative to placebo plus FOLFIRI, from 12.1 months to 13.5 months, respectively. The overall response rate in the aflibercept plus FOLFIRI arm was 19.8% versus 11.1% for placebo plus FOLFIRI (p=0.0001).2

 REFERENCES

  1. Zaltrap Summary of Product Characteristics, February 2013.
  2. Van Cutsem E et al. J Clin Oncol 2012; 30: 3499–506.

View Zaltrap drug record

Further information: Sanofi

Follow MIMS on Twitter

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more